Liver drug combination study for MASH and liver scarring
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests whether taking rezdiffra (a liver medication) together with other common diabetes or liver drugs is safe and effective for adults with MASH (fatty liver disease) and moderate-to-severe liver scarring. It may help improve liver health and reduce disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of MASH (fatty liver disease) with moderate-to-severe liver scarring (stage F2-F3), but no cirrhosis.
- Your liver fat measurement is above 5% as shown by a special MRI.
- You are not currently taking certain medications (like high-dose statins) that could interact with the study drug.
- You have no other liver diseases such as hepatitis or autoimmune liver disease.
- If you are female and could become pregnant, you agree to use effective birth control and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, resmetirom, to see if it can help people who have had a liver transplant for MASH and now have fatty buildup in their new liver. It may also help people who had a transplant for other reasons but developed fatty liver afterward. The study focuses on those with moderate to advanced liver scarring (F2-F3).
This trial tests if resmetirom can help people with MASH, a type of fatty liver disease linked to metabolic issues like diabetes or obesity. It looks at how safe and effective the drug is over time.
This study tests a daily pill, resmetirom, to see if it can reduce fat and scarring in the livers of children and teens with MASH, a type of fatty liver disease. It may help improve liver health and prevent further damage.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This trial tests a drug called resmetirom for people who have both a type of fatty liver disease (MASH) and a type of heart failure (HFpEF). It aims to see if the drug can help both conditions. You may be able to join if you have both conditions and meet certain health criteria.
This registry collects information about the safety of a liver disease medication called Rezdiffra (resmetirom) when used during pregnancy or while breastfeeding. Researchers want to understand if the medication affects the health of pregnant women, babies, and nursing infants.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.